Important Notice for Unicycive Investors
Bragar Eagel & Squire, P.C., a prominent law firm specializing in investor protection, is reaching out to those who have incurred losses in Unicycive Therapeutics, Inc. (NASDAQ: UNCY). If you are an investor who acquired shares in Unicycive during the class period spanning from March 29, 2024, to June 27, 2025, it is essential to discuss your legal options before the imminent deadline.
Contact Information for Legal Support
For direct assistance, contact Brandon Walker or Marion Passmore at (212) 355-4648 to schedule a consultation. This is a crucial step for investors looking to understand their rights under the current circumstances. If you have experienced a decline in your investment value, reaching out is vital.
Upcoming Legal Timeline
The courtroom action against Unicycive is rapidly approaching. Investors have until October 14, 2025, to apply to be named as lead plaintiff in the class action lawsuit. It’s important to be proactive and ensure you are participating before this date to safeguard your interests.
Details of the Class Action Lawsuit
This class action lawsuit arises from allegations regarding Unicycive's misrepresentations about its New Drug Application (NDA) for oxylanthanum carbonate (OLC). According to the lawsuit, Unicycive was accused of overstating its compliance with FDA regulations, which misled investors about the company's prospects.
Allegations Against Unicycive
The complaint alleges that during the class period, Unicycive touted the readiness of its manufacturing practices, assuring investors of compliance with necessary FDA regulations. However, the case claims that these statements were misleading as the company failed to disclose significant compliance issues.
Impact of the Allegations
Moreover, the situation worsened when Unicycive announced that deficiencies were identified by the FDA in their manufacturing processes at a third-party vendor. This revelation led to a dramatic drop in stock prices, impacting many investors significantly.
Next Steps for Affected Investors
If you purchased Unicycive shares and are concerned about potential losses, it is crucial to act swiftly. Whether you are a long-term investor or just acquired stocks recently, you may qualify to take part in the legal proceedings. To get involved or learn more about your options, reach out to Brandon Walker or Marion Passmore directly through the provided contact information.
About Bragar Eagel & Squire, P.C.
Bragar Eagel & Squire, P.C. is a respected law firm known for its commitment to representing investors in complex litigation cases. With a national presence, the firm has successfully advocated for clients in securities and commercial disputes. To learn more about their services and how they can assist you, visit their official webpage.
Frequently Asked Questions
What should Unicycive investors do now?
If you have concerns about your investments in Unicycive, it's vital to contact legal professionals before the upcoming deadline to discuss your options.
What is the deadline for filing claims?
The deadline for investors to apply to be a lead plaintiff in the class action lawsuit is October 14, 2025.
Who can join the class action lawsuit?
Investors who purchased shares of Unicycive between March 29, 2024, and June 27, 2025, and suffered losses are eligible to join the lawsuit.
What are the allegations against Unicycive?
The allegations involve misleading statements regarding the company’s compliance with FDA manufacturing requirements and the impact of compliance issues on its stock value.
How can I contact Bragar Eagel & Squire?
To get in touch, call (212) 355-4648 or email investigations@bespc.com for inquiries regarding your case or potential claims.
